Ippei Miyagawa

1.5k total citations
72 papers, 904 citations indexed

About

Ippei Miyagawa is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Ippei Miyagawa has authored 72 papers receiving a total of 904 indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Rheumatology, 25 papers in Immunology and 16 papers in Hematology. Recurrent topics in Ippei Miyagawa's work include Systemic Lupus Erythematosus Research (26 papers), Rheumatoid Arthritis Research and Therapies (18 papers) and Autoimmune and Inflammatory Disorders Research (12 papers). Ippei Miyagawa is often cited by papers focused on Systemic Lupus Erythematosus Research (26 papers), Rheumatoid Arthritis Research and Therapies (18 papers) and Autoimmune and Inflammatory Disorders Research (12 papers). Ippei Miyagawa collaborates with scholars based in Japan, Germany and Netherlands. Ippei Miyagawa's co-authors include Yoshiya Tanaka, Shingo Nakayamada, Satoshi Kubo, Kazuhisa Nakano, S. Iwata, Yusuke Miyazaki, Kazuyoshi Saito, Kentaro Hanami, Maiko Yoshikawa and Shunsuke Fukuyo and has published in prestigious journals such as The Journal of Immunology, PLoS ONE and IEEE Transactions on Pattern Analysis and Machine Intelligence.

In The Last Decade

Ippei Miyagawa

64 papers receiving 894 citations

Peers

Countries citing papers authored by Ippei Miyagawa

Since Specialization

Citations

This map shows the geographic impact of Ippei Miyagawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ippei Miyagawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ippei Miyagawa more than expected).

Fields of papers citing papers by Ippei Miyagawa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ippei Miyagawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ippei Miyagawa. The network helps show where Ippei Miyagawa may publish in the future.

Co-authorship network of co-authors of Ippei Miyagawa

This figure shows the co-authorship network connecting the top 25 collaborators of Ippei Miyagawa. A scholar is included among the top collaborators of Ippei Miyagawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ippei Miyagawa. Ippei Miyagawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Precision medicine using molecular-target drugs in psoriatic arthritis 2025 ·Therapeutic Advances in Musculoskeletal Disease ·Ippei Miyagawa, Yoshiya Tanaka	1
2	Transition of clinical remission rates with molecular targeted therapies in rheumatoid arthritis in Japan: insights from the FIRST registry 2025 ·Lara D. Veeken ·(unknown), Yusuke Miyazaki, (unknown), Yuya Fujita, (unknown), Masanobu Ueno, Yasuyuki Todoroki, (unknown), Ippei Miyagawa, Shingo Nakayamada, Yoshiya Tanaka	1
3	Effective Second-Line b/tsDMARDs for Patients with Rheumatoid Arthritis Unresponsive to First-Line b/tsDMARDs from the FIRST Registry 2025 ·Rheumatology and Therapy ·(unknown), Yusuke Miyazaki, Shingo Nakayamada, Shunsuke Fukuyo, Satoshi Kubo, Ippei Miyagawa, Ayako Yamaguchi, (unknown), Naoaki Ohkubo, Yasuyuki Todoroki, Hiroaki Tanaka, Masanobu Ueno, Atsushi Nagayasu, (unknown), (unknown), (unknown), H. Sakai, (unknown), (unknown), Yoshiya Tanaka	2
4	Efficacy, safety and optimal intervention of belimumab for proliferative lupus nephritis patients in real-world settings: LOOPS registry 2024 ·Lara D. Veeken ·H. Sakai, Yusuke Miyazaki, Shingo Nakayamada, Satoshi Kubo, Kentaro Hanami, Shunsuke Fukuyo, Ayako Yamaguchi, Ippei Miyagawa, (unknown), (unknown), Yasuyuki Todoroki, Naoaki Ohkubo, (unknown), (unknown), Yoshiya Tanaka	1
5	Induction of interleukin 21 receptor expression via enhanced intracellular metabolism in B cells and its relevance to the disease activity in systemic lupus erythematosus 2024 ·RMD Open ·(unknown), S. Iwata, Kaoru Yamagata, Yasuyuki Todoroki, Koshiro Sonomoto, Atsushi Nagayasu, Ippei Miyagawa, Satoshi Kubo, Yusuke Miyazaki, (unknown), (unknown), (unknown), Shingo Nakayamada, Yoshiya Tanaka	1
6	Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness 2024 ·Annals of the Rheumatic Diseases ·Satoshi Kubo, Yusuke Miyazaki, T Nishino, (unknown), (unknown), (unknown), Kazuyoshi Ishigaki, (unknown), Hiroaki Tanaka, (unknown), (unknown), Yoshino Inoue, Yasuyuki Todoroki, Ippei Miyagawa, Kentaro Hanami, Shingo Nakayamada, Yoshiya Tanaka	8
7	A case of Erdheim–Chester disease—a mimicker of IgG4-related disease and large vessel vasculitis 2024 ·Modern Rheumatology Case Reports ·Ippei Miyagawa, Shingo Nakayamada, (unknown), (unknown), Masanobu Ueno, Yoshiya Tanaka	0
8	Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry 2023 ·Lara D. Veeken ·Yusuke Miyazaki, (unknown), Shingo Nakayamada, Koshiro Sonomoto, Hiroaki Tanaka, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Ayako Yamaguchi, Ippei Miyagawa, Yasuyuki Todoroki, Masanobu Ueno, Yoshiya Tanaka	8
9	Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study 2022 ·Arthritis Research & Therapy ·Masanobu Ueno, Ippei Miyagawa, (unknown), Koichi Kimura, S. Iwata, Kentaro Hanami, (unknown), Satoshi Kubo, Yusuke Miyazaki, Shingo Nakayamada, Yoshiya Tanaka	17
10	Precision medicine based on the phenotypic differences in peripheral T helper cells in patients with psoriatic arthritis: One year follow-up outcomes 2022 ·Frontiers in Medicine ·Ippei Miyagawa, Shingo Nakayamada, Masanobu Ueno, Yusuke Miyazaki, Naoaki Ohkubo, Yoshino Inoue, Satoshi Kubo, Yoshiya Tanaka	5
11	Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study 2022 ·Arthritis Research & Therapy ·Ippei Miyagawa, Shingo Nakayamada, Masanobu Ueno, Yusuke Miyazaki, S. Iwata, Satoshi Kubo, Koshiro Sonomoto, (unknown), Naoaki Ohkubo, Yoshino Inoue, Yoshiya Tanaka	9
12	Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis 2021 ·Arthritis Research & Therapy ·Masanobu Ueno, Ippei Miyagawa, Kazuhisa Nakano, S. Iwata, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Yusuke Miyazaki, (unknown), (unknown), Shingo Nakayamada, Yoshiya Tanaka	25
13	Systemic lupus erythematosus with repeated protein-losing enteropathy resulting from different pathological conditions: a case report 2020 ·Modern Rheumatology Case Reports ·(unknown), Kazuhisa Nakano, Ippei Miyagawa, Masanobu Ueno, Yoshiya Tanaka	2
14	The approach to precision medicine for the treatment of psoriatic arthritis 2020 ·Immunological Medicine ·Ippei Miyagawa, Yoshiya Tanaka	5
15	The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus 2020 ·International Journal of Rheumatic Diseases ·Ippei Miyagawa, Kazuhisa Nakano, Shingo Nakayamada, S. Iwata, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, (unknown), Yusuke Miyazaki, Yoshino Inoue, Masanobu Ueno, Naoaki Ohkubo, (unknown), Yoshiya Tanaka	10
16	Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus 2018 ·International Journal of Rheumatic Diseases ·Ippei Miyagawa, Kazuhisa Nakano, Shingo Nakayamada, S. Iwata, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Yoshino Inoue, Masanobu Ueno, Yoshiya Tanaka	15
17	Regulatory Mechanism of The Induction of Regulatory T Cells through Growth Factors Released by Human Mesenchymal Stem Cells 2018 ·Critical Reviews in Immunology ·Ippei Miyagawa, Shingo Nakayamada, Masahiro Kondo, Yoshiya Tanaka	5
18	Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis 2017 ·Lara D. Veeken ·Shingo Nakayamada, Satoshi Kubo, Maiko Yoshikawa, Yusuke Miyazaki, (unknown), S. Iwata, Ippei Miyagawa, Shintaro Hirata, Kazuhisa Nakano, Kazuyoshi Saito, Yoshiya Tanaka	71
19	Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching 2015 ·Annals of the Rheumatic Diseases ·Satoshi Kubo, Shingo Nakayamada, Kazuhisa Nakano, Shintaro Hirata, Shunsuke Fukuyo, Ippei Miyagawa, Kentaro Hanami, Kazuyoshi Saito, Yoshiya Tanaka	39
20	Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept 2011 ·Modern Rheumatology ·Yoshiya Tanaka, Hisashi Yamanaka, Kazuyoshi Saito, (unknown), Ippei Miyagawa, Yohei Seto, Shigeki Momohara, Hayato Nagasawa, Hideto Kameda, Yuko Kaneko, Keisuke Izumi, Koichi Amano, Tsutomu Takeuchi	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact